Brought to you by 
HalioDx, NanoString develop gene expression assays for immunotherapies
27 Oct 2021
Executive Summary
Molecular diagnostic firms HalioDx SAS and NanoString Technologies Inc. will collaborate on the development of gene expression assays to evaluate patient response to immunotherapeutics.
Deal Industry
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Immuno-Oncology
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
HalioDx, NanoString develop gene expression assays for immunotherapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice